This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

This study has been completed.
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC Identifier:
First received: April 9, 2007
Last updated: April 19, 2013
Last verified: April 2013

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with cisplatin may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects and how well giving bortezomib together with cisplatin works as first-line therapy in treating patients with malignant mesothelioma.

Condition Intervention Phase
Malignant Mesothelioma Drug: bortezomib Drug: cisplatin Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Bortezomib (VELCADE) With Cisplatin as First Line Treatment of Malignant Mesothelioma

Resource links provided by NLM:

Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Primary Outcome Measures:
  • Progression-free survival (PFS) rate at 18 weeks

Secondary Outcome Measures:
  • Overall objective response rate
  • Symptomatic response rate
  • Safety as measured by NCI CTCAE v3.0 and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire
  • Duration of PFS
  • Overall survival

Enrollment: 82
Study Start Date: February 2007
Study Completion Date: March 2012
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the activity and safety of bortezomib and cisplatin as first-line treatment in patients with malignant mesothelioma.
  • Validate the use of progression-free survival rate as a primary endpoint for the design of phase II mesothelioma trials.

OUTLINE: This is a nonrandomized, open-label, multicenter study.

Patients receive cisplatin IV over 1 hour on day 1 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically.

PROJECTED ACCRUAL: A total of 76 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed pleural malignant mesothelioma, meeting 1 of the following criteria:

    • Recurrent disease after radical surgery
    • Disease not considered suitable for radical treatment
  • Measurable or evaluable disease
  • No clinical evidence of brain or leptomeningeal metastases


  • WHO performance status 0-1
  • Life expectancy > 12 weeks
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Absolute neutrophil count > 1,500/mm³
  • Platelet count > 100,000/mm³
  • Creatinine clearance > 60 mL/min OR > 50 mL/min
  • ALT and AST < 2.5 times upper limit of normal (ULN) (< 5 times ULN if liver metastases present)
  • Bilirubin < 1.5 times ULN
  • No concurrent secondary malignancy except carcinoma in situ of the cervix or adequately treated basal cell skin cancer
  • No other malignancy treated within the past 5 years

    • Melanoma, breast cancer, or hypernephroma treated within the past 5 years and without recurrence are allowed
  • No uncontrolled or severe cardiovascular disease, including any of the following:

    • Myocardial infarction within the past 6 months
    • New York Heart Association class III-IV heart failure
    • Uncontrolled angina
    • Clinically significant pericardial disease or cardiac amyloidosis
  • No infiltrative pulmonary or pericardial disease
  • No preexisting peripheral neuropathy
  • No known or suspected allergy or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used
  • No psychological, familial, sociological, or geographical condition that would preclude protocol compliance


  • See Disease Characteristics
  • No prior systemic chemotherapy for mesothelioma
  • No other concurrent antineoplastic agents except medications that may have antineoplastic activity but are taken for other reasons (e.g., megestrol acetate, cyclooxygenase-2 inhibitors, or bisphosphonates)
  • No other concurrent experimental agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00458913

United Kingdom
Royal Marsden - Surrey
Sutton, England, United Kingdom, SM2 5PT
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Study Chair: Mary O'Brien, MD Royal Marsden NHS Foundation Trust
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT00458913     History of Changes
Other Study ID Numbers: EORTC-08052
2006-000009-51 ( EudraCT Number )
Study First Received: April 9, 2007
Last Updated: April 19, 2013

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
localized malignant mesothelioma
recurrent malignant mesothelioma
advanced malignant mesothelioma

Additional relevant MeSH terms:
Lung Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Mesothelial
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents processed this record on August 18, 2017